beta-adrenergic receptor agonist
Jump to navigation
Jump to search
Adverse effects
- hypokalemia, intracellular shift of K+
- metabolic acidosis
- hypomagnesemia
- tachycardia
- tremor
- anxiety
- palpitations
- hypertension
- cardiac arrhythmias
- exacerbation of prostatism
- paradoxic bronchospasm to aerosolized beta-adrenergic agents (especially long-acting agents, salmeterol, formoterol[2]
- tachyphylaxis
- preservatives & propellants
- adverse effects more likely in elderly & in patients with cardiovascular, hepatic & neurologic disorders
- drug adverse effects of adrenergic receptor agonists
- drug adverse effects of beta-adrenergic receptor agonists
- drug adverse effects of sympathomimetic(s)
Drug interactions
- beta adrenergic agonists may potentiate the effects of MAO inhibitors & tricyclic antidepressants
Mechanism of action
- stimulation of cAMP formation in selected cell population
More general terms
More specific terms
- arbutamine
- beta-1 adrenergic receptor agonist
- beta-3 adrenergic receptor agonist
- bitolterol (Tornalate)
- ephedrine
- epinephrine; adrenaline (Sus-Phrine, Vapronefrin, Epifrin, Glaucon, Auvi-Q, Allerject)
- inhaled beta-2 adrenergic receptor agonist
- isoetharine (Bronkosol, Bronkometer)
- isoproterenol
- long-acting beta adrenergic receptor agonist (LABA)
- metaproterenol (Alupent, Metaprel, Dey-Dose)
- pirbuterol (Maxair)
Additional terms
Component of
References
- ↑ Mayo Internal Medicine Board Review, 1998-99, Prakash UBS (ed) Lippincott-Raven, Philadelphia, 1998, pg 741
- ↑ 2.0 2.1 Prescriber's Letter 12(9): 2005 The Safety of Long-Acting Beta-2 Agonists in Patients with Asthma Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210907&pb=PRL (subscription needed) http://www.prescribersletter.com
US Department of Health and Human Services. National Institutes of Health. National Heart, Lung and Blood Institute. Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma-Update on selected topics 2002. - ↑ Salpeter SR et al, Meta-analysis: Effect of long-acting beta agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006; 144:904 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16754916
Glassroth J The role of long-acting beta-agonists in the management of asthma. Analysis, meta-analysis, and more analysis, Ann Intern Med 2006; 144:936 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16754915 - ↑ Bateman E et al, Effects of adding salmeterol in inhaled corticosteroids on serious asthma-related events. Ann Intern Med 2008, June 3 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18523132
Weiss KB Drug safety and salmeterol: The controversy continues. Ann Intern Med 2008, June 3 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18523132